17536 Search Results


atcc 17536 cells  (ATCC)
91
ATCC atcc 17536 cells
Atcc 17536 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/17536/Pseudomonas+putida+biotype+b/10__3390_slash_fermentation9110955-197-2-2
Average 91 stars, based on 1 article reviews
atcc 17536 cells - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
n methyl n tetrahydro  (Chem Impex International)
95
Chem Impex International n methyl n tetrahydro
N Methyl N Tetrahydro, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/17536/N-Methyl-N-tetrahydro-2H-pyran-4-ylamine/us08513239-1052-16-17
Average 95 stars, based on 1 article reviews
n methyl n tetrahydro - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
sorafenib  (MedChemExpress)
94
MedChemExpress sorafenib
Inhibitory effect of combined selinexor and <t>sorafenib</t> on xenograft tumor growth in nude mice. (A) Photographs of final tumor volumes from different treatment groups. (B) Quantitative bar graph of final tumor volumes from different treatment groups. (C) Photographs of the final tumor weights from different treatment groups. (D) Quantitative bar graph of the final tumor weights from different treatment groups. (mean ± SD, n=5; Sel-10 = selinexor monotherapy (10 mg/kg), Sor-10 = sorafenib monotherapy (10 mg/kg), Sel-10 + Sor-10 = selinexor + sorafenib combination (10 mg/kg + 10 mg/kg); *P < 0.05, **P <0.01, ***P <0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test). (Refer to <xref ref-type=Table 1 for detailed measured tumor volume data at key time points during the entire treatment period). " width="250" height="auto" />
Sorafenib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/17536/Selinexor/pmc13002423-33-7-11
Average 94 stars, based on 1 article reviews
sorafenib - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
pexpres 2 1  (Addgene inc)
93
Addgene inc pexpres 2 1
Inhibitory effect of combined selinexor and <t>sorafenib</t> on xenograft tumor growth in nude mice. (A) Photographs of final tumor volumes from different treatment groups. (B) Quantitative bar graph of final tumor volumes from different treatment groups. (C) Photographs of the final tumor weights from different treatment groups. (D) Quantitative bar graph of the final tumor weights from different treatment groups. (mean ± SD, n=5; Sel-10 = selinexor monotherapy (10 mg/kg), Sor-10 = sorafenib monotherapy (10 mg/kg), Sel-10 + Sor-10 = selinexor + sorafenib combination (10 mg/kg + 10 mg/kg); *P < 0.05, **P <0.01, ***P <0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test). (Refer to <xref ref-type=Table 1 for detailed measured tumor volume data at key time points during the entire treatment period). " width="250" height="auto" />
Pexpres 2 1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/17536/pJU216+(Plasmid+%2317536)/pmc09117644-8-0-3
Average 93 stars, based on 1 article reviews
pexpres 2 1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
p putida atcc 17536  (ATCC)
90
ATCC p putida atcc 17536
Inhibitory effect of combined selinexor and <t>sorafenib</t> on xenograft tumor growth in nude mice. (A) Photographs of final tumor volumes from different treatment groups. (B) Quantitative bar graph of final tumor volumes from different treatment groups. (C) Photographs of the final tumor weights from different treatment groups. (D) Quantitative bar graph of the final tumor weights from different treatment groups. (mean ± SD, n=5; Sel-10 = selinexor monotherapy (10 mg/kg), Sor-10 = sorafenib monotherapy (10 mg/kg), Sel-10 + Sor-10 = selinexor + sorafenib combination (10 mg/kg + 10 mg/kg); *P < 0.05, **P <0.01, ***P <0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test). (Refer to <xref ref-type=Table 1 for detailed measured tumor volume data at key time points during the entire treatment period). " width="250" height="auto" />
P Putida Atcc 17536, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/17536/Pseudomonas+putida+(Trevisan)+Migula/10__3390_slash_fermentation9110955-195-1-3
Average 90 stars, based on 1 article reviews
p putida atcc 17536 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
trpa1 modulators  (Glenmark Inc)
86
Glenmark Inc trpa1 modulators
Inhibitory effect of combined selinexor and <t>sorafenib</t> on xenograft tumor growth in nude mice. (A) Photographs of final tumor volumes from different treatment groups. (B) Quantitative bar graph of final tumor volumes from different treatment groups. (C) Photographs of the final tumor weights from different treatment groups. (D) Quantitative bar graph of the final tumor weights from different treatment groups. (mean ± SD, n=5; Sel-10 = selinexor monotherapy (10 mg/kg), Sor-10 = sorafenib monotherapy (10 mg/kg), Sel-10 + Sor-10 = selinexor + sorafenib combination (10 mg/kg + 10 mg/kg); *P < 0.05, **P <0.01, ***P <0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test). (Refer to <xref ref-type=Table 1 for detailed measured tumor volume data at key time points during the entire treatment period). " width="250" height="auto" />
Trpa1 Modulators, supplied by Glenmark Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/17536/17536+compound+grc/pm24819048-14-41-8
Average 86 stars, based on 1 article reviews
trpa1 modulators - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
grc-17536  (TargetMol)
N/A
   Buy from Supplier

Image Search Results


Inhibitory effect of combined selinexor and sorafenib on xenograft tumor growth in nude mice. (A) Photographs of final tumor volumes from different treatment groups. (B) Quantitative bar graph of final tumor volumes from different treatment groups. (C) Photographs of the final tumor weights from different treatment groups. (D) Quantitative bar graph of the final tumor weights from different treatment groups. (mean ± SD, n=5; Sel-10 = selinexor monotherapy (10 mg/kg), Sor-10 = sorafenib monotherapy (10 mg/kg), Sel-10 + Sor-10 = selinexor + sorafenib combination (10 mg/kg + 10 mg/kg); *P < 0.05, **P <0.01, ***P <0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test). (Refer to <xref ref-type=Table 1 for detailed measured tumor volume data at key time points during the entire treatment period). " width="100%" height="100%">

Journal: Frontiers in Oncology

Article Title: Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway

doi: 10.3389/fonc.2026.1762822

Figure Lengend Snippet: Inhibitory effect of combined selinexor and sorafenib on xenograft tumor growth in nude mice. (A) Photographs of final tumor volumes from different treatment groups. (B) Quantitative bar graph of final tumor volumes from different treatment groups. (C) Photographs of the final tumor weights from different treatment groups. (D) Quantitative bar graph of the final tumor weights from different treatment groups. (mean ± SD, n=5; Sel-10 = selinexor monotherapy (10 mg/kg), Sor-10 = sorafenib monotherapy (10 mg/kg), Sel-10 + Sor-10 = selinexor + sorafenib combination (10 mg/kg + 10 mg/kg); *P < 0.05, **P <0.01, ***P <0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test). (Refer to Table 1 for detailed measured tumor volume data at key time points during the entire treatment period).

Article Snippet: Selinexor was purchased from Selleck Chemicals, and sorafenib was obtained from MedChemExpress (MCE).

Techniques:

Immunohistochemical detection results of related proteins (BAX, Bcl-2, p27, and XPO1) in xenograft tumor tissues of nude mice from different treatment groups. (A) Representative immunohistochemical images of BAX, Bcl-2, p27, and XPO1 expression (magnification=40×; scale bar=50 μm). (B) Quantitative analysis of BAX expression among treatment groups. (C) Quantitative analysis of Bcl-2 expression among treatment groups. (D) Quantitative analysis of p27 expression among treatment groups. (E) Quantitative analysis of XPO1 expression among treatment groups. (Quantitative analysis of immunohistochemical staining intensity: mean ± SD, n=5 fields per section; Sel-10 = selinexor monotherapy (10 mg/kg), Sor-10 = sorafenib monotherapy (10 mg/kg), Sel-10 + Sor-10 = selinexor + sorafenib combination (10 mg/kg + 10 mg/kg); *P < 0.05, **P <0.01, ***P <0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test). Coordinated modulation of BAX and Bcl-2 in tumor tissues is consistent with in vitro PUMA upregulation, supporting the functional activation of the BAX/Bcl-2/PUMA apoptotic pathway in vivo (refer to Section 3.1 and Discussion for details).

Journal: Frontiers in Oncology

Article Title: Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway

doi: 10.3389/fonc.2026.1762822

Figure Lengend Snippet: Immunohistochemical detection results of related proteins (BAX, Bcl-2, p27, and XPO1) in xenograft tumor tissues of nude mice from different treatment groups. (A) Representative immunohistochemical images of BAX, Bcl-2, p27, and XPO1 expression (magnification=40×; scale bar=50 μm). (B) Quantitative analysis of BAX expression among treatment groups. (C) Quantitative analysis of Bcl-2 expression among treatment groups. (D) Quantitative analysis of p27 expression among treatment groups. (E) Quantitative analysis of XPO1 expression among treatment groups. (Quantitative analysis of immunohistochemical staining intensity: mean ± SD, n=5 fields per section; Sel-10 = selinexor monotherapy (10 mg/kg), Sor-10 = sorafenib monotherapy (10 mg/kg), Sel-10 + Sor-10 = selinexor + sorafenib combination (10 mg/kg + 10 mg/kg); *P < 0.05, **P <0.01, ***P <0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test). Coordinated modulation of BAX and Bcl-2 in tumor tissues is consistent with in vitro PUMA upregulation, supporting the functional activation of the BAX/Bcl-2/PUMA apoptotic pathway in vivo (refer to Section 3.1 and Discussion for details).

Article Snippet: Selinexor was purchased from Selleck Chemicals, and sorafenib was obtained from MedChemExpress (MCE).

Techniques: Immunohistochemical staining, Expressing, Staining, In Vitro, Functional Assay, Activation Assay, In Vivo

Inhibitory effects of selinexor and sorafenib monotherapy on HCC cell proliferation (CCK-8 assay) (n=3). (A) Inhibitory effect of selinexor at different concentrations on Huh7 cell proliferation (24h, 48h, 72h). (B) Inhibitory effect of sorafenib at different concentrations on Huh7 cell proliferation (24h, 48h, 72h). (C) Inhibitory effect of selinexor at different concentrations on SK-HEP-1 cell proliferation (24h, 48h, 72h). (D) Inhibitory effect of sorafenib at different concentrations on SK-HEP-1 cell proliferation (24h, 48h, 72h). (E) Inhibitory effect of selinexor at different concentrations on HepG2 cell proliferation (24h, 48h, 72h). (F) Inhibitory effect of sorafenib at different concentrations on HepG2 cell proliferation (24h, 48h, 72h). (mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001; statistical significance was determined by two-way ANOVA followed by Bonferroni post-hoc test). (The IC 50 values of selinexor and sorafenib against Huh7, SK-HEP-1, and HepG2 cells at 72 h are provided in the main text (Section 3.2)).

Journal: Frontiers in Oncology

Article Title: Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway

doi: 10.3389/fonc.2026.1762822

Figure Lengend Snippet: Inhibitory effects of selinexor and sorafenib monotherapy on HCC cell proliferation (CCK-8 assay) (n=3). (A) Inhibitory effect of selinexor at different concentrations on Huh7 cell proliferation (24h, 48h, 72h). (B) Inhibitory effect of sorafenib at different concentrations on Huh7 cell proliferation (24h, 48h, 72h). (C) Inhibitory effect of selinexor at different concentrations on SK-HEP-1 cell proliferation (24h, 48h, 72h). (D) Inhibitory effect of sorafenib at different concentrations on SK-HEP-1 cell proliferation (24h, 48h, 72h). (E) Inhibitory effect of selinexor at different concentrations on HepG2 cell proliferation (24h, 48h, 72h). (F) Inhibitory effect of sorafenib at different concentrations on HepG2 cell proliferation (24h, 48h, 72h). (mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001; statistical significance was determined by two-way ANOVA followed by Bonferroni post-hoc test). (The IC 50 values of selinexor and sorafenib against Huh7, SK-HEP-1, and HepG2 cells at 72 h are provided in the main text (Section 3.2)).

Article Snippet: Selinexor was purchased from Selleck Chemicals, and sorafenib was obtained from MedChemExpress (MCE).

Techniques: CCK-8 Assay

Inhibitory effects of combined selinexor and sorafenib on HCC cell proliferation (CCK-8 assay) (n=3). (A) Effect of combined selinexor and sorafenib on Huh7 cell proliferation (48h). (B) Effect of combined selinexor and sorafenib on Huh7 cell proliferation (72h). (C) Effect of combined selinexor and sorafenib on SK-HEP-1 cell proliferation (48h). (D) Effect of combined selinexor and sorafenib on SK-HEP-1 cell proliferation (72h). (E) Effect of combined selinexor and sorafenib on HepG2 cell proliferation (48h). (F) Effect of combined selinexor and sorafenib on HepG2 cell proliferation (72h). (mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test).

Journal: Frontiers in Oncology

Article Title: Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway

doi: 10.3389/fonc.2026.1762822

Figure Lengend Snippet: Inhibitory effects of combined selinexor and sorafenib on HCC cell proliferation (CCK-8 assay) (n=3). (A) Effect of combined selinexor and sorafenib on Huh7 cell proliferation (48h). (B) Effect of combined selinexor and sorafenib on Huh7 cell proliferation (72h). (C) Effect of combined selinexor and sorafenib on SK-HEP-1 cell proliferation (48h). (D) Effect of combined selinexor and sorafenib on SK-HEP-1 cell proliferation (72h). (E) Effect of combined selinexor and sorafenib on HepG2 cell proliferation (48h). (F) Effect of combined selinexor and sorafenib on HepG2 cell proliferation (72h). (mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test).

Article Snippet: Selinexor was purchased from Selleck Chemicals, and sorafenib was obtained from MedChemExpress (MCE).

Techniques: CCK-8 Assay

Regulatory effects of combined selinexor and sorafenib on cell cycle distribution of HCC cells (n=3). (A) Cell cycle distribution of Huh7 cells in the blank control group. (B) Cell cycle distribution of Huh7 cells in the sorafenib group. (C) Cell cycle distribution of Huh7 cells in the selinexor group. (D) Cell cycle distribution of Huh7 cells in the selinexor + sorafenib group. (E) Quantitative analysis of cell cycle distribution in Huh7 cells. (F) Cell cycle distribution of HepG2 cells in the blank control group. (G) Cell cycle distribution of HepG2 cells in the sorafenib group. (H) Cell cycle distribution of HepG2 cells in the selinexor group. (I) Cell cycle distribution of HepG2 cells in the selinexor + sorafenib group. (J) Quantitative analysis of cell cycle distribution in HepG2 cells. (Quantitative analysis of cell cycle phase proportions: mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test).

Journal: Frontiers in Oncology

Article Title: Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway

doi: 10.3389/fonc.2026.1762822

Figure Lengend Snippet: Regulatory effects of combined selinexor and sorafenib on cell cycle distribution of HCC cells (n=3). (A) Cell cycle distribution of Huh7 cells in the blank control group. (B) Cell cycle distribution of Huh7 cells in the sorafenib group. (C) Cell cycle distribution of Huh7 cells in the selinexor group. (D) Cell cycle distribution of Huh7 cells in the selinexor + sorafenib group. (E) Quantitative analysis of cell cycle distribution in Huh7 cells. (F) Cell cycle distribution of HepG2 cells in the blank control group. (G) Cell cycle distribution of HepG2 cells in the sorafenib group. (H) Cell cycle distribution of HepG2 cells in the selinexor group. (I) Cell cycle distribution of HepG2 cells in the selinexor + sorafenib group. (J) Quantitative analysis of cell cycle distribution in HepG2 cells. (Quantitative analysis of cell cycle phase proportions: mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test).

Article Snippet: Selinexor was purchased from Selleck Chemicals, and sorafenib was obtained from MedChemExpress (MCE).

Techniques: Control

Apoptosis-inducing effects of combined selinexor and sorafenib on HCC cells (n=3). (A) Apoptotic rate of Huh7 cells in the blank control group. (B) Apoptotic rate of Huh7 cells in the sorafenib group. (C) Apoptotic rate of Huh7 cells in the selinexor group. (D) Apoptotic rate of Huh7 cells in the selinexor + sorafenib group. (E) Quantitative analysis of apoptotic rate in Huh7 cells. (F) Apoptotic rate of HepG2 cells in the blank control group. (G) Apoptotic rate of HepG2 cells in the sorafenib group. (H) Apoptotic rate of HepG2 cells in the selinexor group. (I) Apoptotic rate of HepG2 cells in the selinexor + sorafenib group. (J) Quantitative analysis of apoptotic rate in HepG2 cells. (Quantitative analysis of total apoptotic rates (early + late apoptosis): mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test).

Journal: Frontiers in Oncology

Article Title: Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway

doi: 10.3389/fonc.2026.1762822

Figure Lengend Snippet: Apoptosis-inducing effects of combined selinexor and sorafenib on HCC cells (n=3). (A) Apoptotic rate of Huh7 cells in the blank control group. (B) Apoptotic rate of Huh7 cells in the sorafenib group. (C) Apoptotic rate of Huh7 cells in the selinexor group. (D) Apoptotic rate of Huh7 cells in the selinexor + sorafenib group. (E) Quantitative analysis of apoptotic rate in Huh7 cells. (F) Apoptotic rate of HepG2 cells in the blank control group. (G) Apoptotic rate of HepG2 cells in the sorafenib group. (H) Apoptotic rate of HepG2 cells in the selinexor group. (I) Apoptotic rate of HepG2 cells in the selinexor + sorafenib group. (J) Quantitative analysis of apoptotic rate in HepG2 cells. (Quantitative analysis of total apoptotic rates (early + late apoptosis): mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test).

Article Snippet: Selinexor was purchased from Selleck Chemicals, and sorafenib was obtained from MedChemExpress (MCE).

Techniques: Control

Effects of combined selinexor and sorafenib on the expression of apoptosis- and cell cycle-related proteins (BAX, Bcl-2, p27, XPO1, PUMA) in Huh7 cells (n=3). (A) The protein expressions of BAX, Bcl-2, p27, XPO1, PUMA by Western Blot. (B) BAX protein data analysis. (C) Bcl-2 protein data analysis. (D) p27 protein data analysis. (E) XPO1 protein data analysis. (F) PUMA protein data analysis. (Quantitative analysis of protein expression levels (normalized to GAPDH): mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test).

Journal: Frontiers in Oncology

Article Title: Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway

doi: 10.3389/fonc.2026.1762822

Figure Lengend Snippet: Effects of combined selinexor and sorafenib on the expression of apoptosis- and cell cycle-related proteins (BAX, Bcl-2, p27, XPO1, PUMA) in Huh7 cells (n=3). (A) The protein expressions of BAX, Bcl-2, p27, XPO1, PUMA by Western Blot. (B) BAX protein data analysis. (C) Bcl-2 protein data analysis. (D) p27 protein data analysis. (E) XPO1 protein data analysis. (F) PUMA protein data analysis. (Quantitative analysis of protein expression levels (normalized to GAPDH): mean ± SD, n=3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using one-way ANOVA followed by LSD- t test).

Article Snippet: Selinexor was purchased from Selleck Chemicals, and sorafenib was obtained from MedChemExpress (MCE).

Techniques: Expressing, Western Blot